NCT01007383已完成1 期
LEO 27847 - A Phase 1, Double-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- LEO Pharma
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Adverse events
研究概览
简要总结
The purpose of this first-in-man trial is to determine the safety and tolerability of ascending single and multiple doses of LEO 27847 in healthy male subjects. The trial will be performed in two parts. In Part 1, single doses of LEO 27847 will be administered to healthy male subjects. In Part 2, multiple doses of LEO 27847 will be administered to healthy male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Subjects will be male between 18 and 45 years of age, with body mass index (BMI) between 18 and 32 kg/m2 inclusive.
- •Subjects will have a minimum weight of 50 kg
- •Subjects must be in good health, as determined by a medical history, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations (congenital non-haemolytic hyperbilirubinaemia is acceptable)
- •Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions
排除标准
- •Male subjects who are not willing to use appropriate contraception (such as condom) and for female partners; occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository) from the time of the first dose until 3 months after the final dosing occasion.
- •Subjects who have received any prescribed systemic or topical medication within 7 days of the first dose administration unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety
- •Subjects who have used any non-prescribed systemic or topical medication (including herbal remedies) within 7 days of the first dose administration unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety
- •Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of the first dose administration unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety
- •Subjects who are still participating in a clinical study (e.g. attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity), or a marketed drug within the past 3 months prior to the first dosing occasion.
- •Subjects who have donated any blood, plasma or platelets in the month prior to screening or who have made donations on more than two occasions within the 12 months preceding the first dose administration
- •Subjects with a significant history of drug allergy as determined by the Investigator
- •Subjects who have any clinically significant allergic disease (excluding non-active hayfever) as determined by the Investigator
- •Subjects who have a supine blood pressure and supine pulse rate at screening higher than 140/90 mmHg and 100 beats per minute (bpm), respectively, or lower than 90/50 mmHg and 50 bpm, respectively. Healthy young males with a pulse rate of between 45 and 50 bpm may be included at the discretion of the investigator.
- •Subjects who consume more than 28 units (males) of alcohol per week or who have a significant history of alcoholism or drug/chemical abuse as determined by the Investigator (one unit of alcohol equals ½ pint [285 mL] of beer or lager, one glass [125 mL] of wine, or 1/6 gill [25 mL] of spirits)
- •Subjects who smoke more than 15 cigarettes or the equivalent in tobacco per day
- •Subjects with, or with a history of, any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological, dermatological or other major disorders as determined by the Investigator
- •Subjects who have had a clinically significant illness within 4 weeks of the start of dose administration as determined by the Investigator
- •Subjects who are known to have hepatitis, or who are carriers of the hepatitis B surface antigen (HBsAg) or hepatitis C antibody, or who have a positive result to the test for HIV antibodies
- •Subjects who, in the opinion of their General Practitioner (GP) or the Investigator, should not participate in the study, including subjects suspected for whatever reason of not being able to comply with the requirements of the protocol
研究组 & 干预措施
LEO 27847 oral solution (0.05 mg/mL)
Experimental
LEO 27847
干预措施: LEO 27847 (Drug)
LEO 27847 oral solution (0.75 mg/mL)
Experimental
LEO 27847
干预措施: LEO 27847 (Drug)
LEO 27847 oral solution (placebo)
Placebo Comparator
Placebo
干预措施: LEO 27847 (Drug)
结局指标
主要结局
Adverse events
时间窗: 7 days after last dosing
次要结局
- LEO 27847 in blood and urine(72 hours after dosing)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy SubjectsPsoriasis VulgarisNCT00833872LEO Pharma58
已完成
1 期
LEO 32731 - A Study in Healthy Male SubjectsHealthy SubjectsNCT01310049LEO Pharma111
已完成
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy AdultsHIV InfectionsNCT06012136ViiV Healthcare85
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy VolunteersHealthy VolunteersNCT02413255Takeda120
已完成
1 期
A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy ParticipantsHealthyNCT05481333Regeneron Pharmaceuticals64